HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 56 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $57,000 | – | 11,280 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Novo Holdings A/S | 1,280,185 | $5,582,000 | 0.54% |
| Cormorant Asset Management, LP | 201,000 | $876,000 | 0.10% |
| PUTNAM INVESTMENTS LLC | 575,692 | $2,510,000 | 0.01% |
| Alyeska Investment Group, L.P. | 89,722 | $391,000 | 0.00% |
| BLACKROCK ADVISORS LLC | 463,200 | $2,020,000 | 0.00% |
| Sonora Investment Management, LLC | 1,500 | $7,000 | 0.00% |
| SECURIAN ASSET MANAGEMENT, INC | 14,008 | $61,000 | 0.00% |
| MACKENZIE FINANCIAL CORP | 29,208 | $127,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 336 | $1,000 | 0.00% |
| MORGAN STANLEY | 12 | $0 | 0.00% |